Direct-acting antivirals failed to reduce the incidence of hepatocellular carcinoma occurrence in hepatitis C virus associated cirrhosis: A real-world study

Table 1 Baseline characteristics of the direct-acting antiviral agents treatment group (n = 236) and the non-antiviral treatment group (n = 118), n (%)

Variables	DAA treatment(n = 236)	Non-antiviral (n = 118)	t/Z/χ2	P value
Ages (yr)	55.01 ± 9.52	53.69 ± 10.07	1.208	0.228
Male	120 (50.85)	68 (57.63)	1.452	0.228
Cirrhosis (compensate)	187 (79.24)	90 (76.27)	0.407	0.524
Nonspecific liver nodules	191 (80.25)	100/18 (15.13)	0.782	0.377
Child-Pugh (A/B/C)	177/51/8	83/30/5	0.887	0.642
Genotype (1a/1b/2a/3a/3b/6a)	1/156/48/11/11/9	0/73/21/7/7/10	4.663	0.458
lg (HCV RNA) IU/mL	6 (5.6)	5 (4.6)	-2.191	0.028
Along with the disease
Diabetes	51 (21.61)	30 (25.42)	0.648	0.421
Fatty liver	52 (22.03)	13 (11.02)	6.370	0.012
Hypertension	50 (21.19)	23 (19.49)	0.138	0.710
FIB-4	5.27 (3.51, 8.16)	4.94 (2.30, 6.38)	-0.032	0.975
CEA (ng/mL)	3.27 (2.22, 4.86)	2.76 (1.45, 4.70)	-1.015	0.310
AFP (ng/mL)	9,28 (5.15, 19.60)	9.58 (4.27, 17.89)	-2.919	0.004
PIVKA-II (mAU/mL)	24 (18, 32)	24 (21, 35.5)	-1.190	0.234
PLT (109/L)	108.02 ± 61.66	110.66 ± 65.68	-0.342	0.733
CAP (dB/m)	232.76 ± 45.35	241.15 ± 53.59	-0.986	0.325
LSM (kPa)	26.15 ± 16.90	29.50 ± 16.61	-1.269	0.206

DAAs: Direct-acting antiviral agents; HCV RNA was calculated by denary logarithm expressed as lg (HCV RNA); FIB-4: The Fibrosis-4 index; ALBI: The albumin-Bilirubin score; CEA: Carcinoembryonic antigen; AFP: Alpha fetoprotein; PIVKA-II: Vitamin K Absence or Antagonist-II; PLT: Platelet; CAP: Controlled attenuation parameter; LSM: Liver stiffness measurement; PSM: Propensity score matching.